Abstract Number: 1411 • ACR Convergence 2023
Prevalence of Early Axial Spondyloarthritis in the Be-GIANT Cohort Based on the ASAS Consensus Definition of Early Axial Spondyloarthritis
Background/Purpose: Recently, the Assessment of SpondyloArthritis international Society (ASAS) community, led by the ASAS-SPEAR (SPondyloarthritis EARly definition) working group, endorsed a uniform definition for early…Abstract Number: 2439 • ACR Convergence 2023
Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients
Background/Purpose: Recent advances in understanding the biology of Ankylosing Spondylitis (AS) using innovative genomic and proteomic approaches offer the opportunity to address current challenges in…Abstract Number: 0327 • ACR Convergence 2023
Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre
Background/Purpose: The 2021 EULAR guidelines on self-management have made recommendations (rec) to aid with the implementation of self-management strategies in inflammatory arthritis (IA) (1). Their…Abstract Number: 0537 • ACR Convergence 2023
Asynchronous Teleconsultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy as a More Sustainable Model Than Face-to-face Classical Consultation
Background/Purpose: Before COVID pandemic, telehealth use for the followup of rheumatic disease patients had been limited, but nowadays it appears as a more sustainable model…Abstract Number: 1392 • ACR Convergence 2023
Improving the Diagnostic Accuracy in Axial Spondyloarthritis: Interim Results of a Nationwide Telemedicine Project
Background/Purpose: Axial spondyloarthritis (axSpA) is often diagnosed late, while there is also a problem of over- and misdiagnosis in patients with chronic back pain. Imaging,…Abstract Number: 1726 • ACR Convergence 2023
Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis primarily affecting the axial skeleton and commonly coexists with gut and skin inflammation. Currently, patients with…Abstract Number: 2442 • ACR Convergence 2023
Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) patients have irregular neutrophil responses, as indicated clinically by neutrophilia and increased neutrophil to lymphocyte ratios that positively associate with disease…Abstract Number: 0333 • ACR Convergence 2023
Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life
Background/Purpose: Ankylosing spondylitis (AS) leads to symptoms of pain, stiffness, swelling, and fatigue. Patients often report periods of increased symptoms (flares) followed by remission.The purpose…Abstract Number: 0539 • ACR Convergence 2023
Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis
Background/Purpose: Axial SpA (axSpA) and FM manifest with overlapping clinical features such as pain, fatigue, and stiffness, yet their treatment is distinctly different. FM is…Abstract Number: 1394 • ACR Convergence 2023
Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…Abstract Number: 1783 • ACR Convergence 2023
Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis
Background/Purpose: Multiple lines of evidence indicate that ankylosing spondylitis (AS) is a lymphocyte-driven disease. However, which lymphocyte populations are critical in AS pathogenesis is not…Abstract Number: 2545 • ACR Convergence 2023
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study
Background/Purpose: While subcutaneous secukinumab (SEC) is approved for the treatment of axial spondyloarthritis (axSpA), some patients may benefit more from intravenous (IV) administration. This study…Abstract Number: 0500 • ACR Convergence 2023
Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention
Background/Purpose: Selecting patients with the highest probability of long-term retention of biological treatments is important from a clinical and cost-effectiveness point of view. In this…Abstract Number: 0540 • ACR Convergence 2023
The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study
Background/Purpose: In patients (pts) with AS, higher BMI has been linked to higher disease activity1. However, given that BMI can be a poor indicator of…Abstract Number: 1395 • ACR Convergence 2023
Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis
Background/Purpose: Physical activity is part of the treatment of axial spondyloarthritis (axSpA), but despite this almost half of the patients do not meet the required…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 62
- Next Page »